nach oben

Erschienen in:

16.01.2021 | Editorial

Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues

Erschienen in: Hepatology International | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Total eradication of the hepatitis B virus (HBV) is still elusive, as even if HBsAg is lost, covalently closed circular DNA (cccDNA) often persists in the hepatocytes. The currently available drugs for treatment of chronic hepatitis B (CHB) are not able to give sustained off-treatment HBsAg loss (functional cure) in most of the patients, which is the ultimate goal of therapy of CHB and is closest to eradication. In the absence of functional cure, Hepatitis B e antigen (HBeAg) seroconversion and undetectable HBV DNA are taken as end-points of antiviral therapy in HBeAg-positive CHB. …

European Association for the Study of the Liver EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370–398CrossRef

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682–2695CrossRef

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia J, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872–880CrossRef

Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150(134–144):e10

Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, National Collaborative Group on Hepatitis B, India, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102(1):96–104CrossRef

Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial). J Hepatol 2014;61:777–784CrossRef

Chi H, Hansen BE, Guo S, et al. Pegylated interferon Alfa-2b Add-on treatment in hepatitis b virus envelope antigen-positive chronic hepatitis b patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON). J Infect Dis 2017;215:1085–1093CrossRef

Xu W, Li Q, Huang C, et al. Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg positive patients with CHB. Hepatol Int 2020. https://doi.org/10.1007/s12072-020-10095-1CrossRefPubMedPubMedCentral

Sonneveld MJ, Brouwer WP, van der Meer AJ. Posttreatment hepatitis B surface antigen seroreversion: the bane of combination therapy in chronic hepatitis B? Gastroenterology 2016;150:1254–1255CrossRef

10.

Hu P, Shang J, Zhang W, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t) ide Analog: new switch study. J Clin Transl Hepatol 2018;6:25–34CrossRef

11.

Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparing 48 and 96 weeks peginterferon a-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013;62:290–298CrossRef

12.

Chen X, Chen X, Chen W, Ma X, Huang J, Chen R. Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J Med Virol 2014;86:1705–1713CrossRef

13.

Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of tenofovir disoproxil fumarate and peginterferon a-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150:134–144CrossRef

Titel: Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues
Publikationsdatum: 16.01.2021
Erschienen in: Hepatology International / Ausgabe 1/2021
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-020-10129-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy

How can we reduce the impact of COVID-19 pandemic on timely access to liver transplantation in children?

Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates

Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis

S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma

Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin